Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0YVACM
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
AU2017363246B2 Conjugate79A
|
|||||
| Synonyms |
Conjugate79A
Click to Show/Hide
|
|||||
| Organization |
MERSANA THERAPEUTICS, INC.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
15.5
|
|||||
| Structure |
|
|||||
| Antibody Name |
XMT-1535
|
Antibody Info | ||||
| Antigen Name |
Sodium-dependent phosphate transport protein 2B (SLC34A2)
|
Antigen Info | ||||
| Payload Name |
AU2017363246B2+Conjugate79+Payload
|
Payload Info | ||||
| Linker Name |
AU2017363246B2+Conjugate79+Linker
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The ADMET Data Related to This ADC(2027 Update)
Absorption
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 718 | ug*hr/mL |
ADC with an AUC0 to 336 of 3- 402to718 ug·hr/mL.
|
[1] |
Distribution
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 718 | ug*hr/mL |
ADC with an AUC0 to 336 of 3- 402to718 ug·hr/mL.
|
[1] |
Metabolism
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 718 | ug*hr/mL |
ADC with an AUC0 to 336 of 3- 402to718 ug·hr/mL.
|
[1] |
Excretion
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Elimination Half-Life (t1/2) | 202 | hr |
The terminal half-life is 202hr.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 718 | ug*hr/mL |
ADC with an AUC0 to 336 of 3- 402to718 ug·hr/mL.
|
[1] |
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.015 nmol/L | Negative her2 expression (her2-) | ||
| Method Description |
OVCAR3 cell line was plated at 5,000cell/well in black walled 96-well plate and allowed to adhere overnight. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measured
after 10 min using a SpectraMax M5 plate reader (Molecular Devices). Dose response curves were generated using SoftMax Pro software. IC50 values were determined from four-parameter curve fitting
Click to Show/Hide
|
||||
| In Vitro Model | Ovarian carcinoma | OVCAR2 cells | CVCL_3941 | ||